Search Results - "Cruz, Linnaeus Louisse A"

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression by Rivera, Frederick Berro, Lumbang, Grace Nooriza O., Gaid, Danielle Rose Magno, Cruz, Linnaeus Louisse A., Magalong, John Vincent, Bantayan, Nathan Ross B., Lara‐Breitinger, Kyla M., Gulati, Martha, Bakris, George

“…Aim The cardiovascular benefits provided by glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) extend beyond weight reduction and glycaemic control. One…”
Get full text

Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials by Rivera, Frederick Berro, Cruz, Linnaeus Louisse A., Magalong, John Vincent, Ruyeras, Jade Monica Marie J., Aparece, John Paul, Bantayan, Nathan Ross B., Lara-Breitinger, Kyla, Gulati, Martha

“…•This is the largest meta-analysis of placebo-controlled GLP-1RA randomized controlled trials to report cardiovascular and renal outcomes among patients with…”
Get full text

Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression by Rivera, Frederick Berro, Cha, Sung Whoy, Magalong, John Vincent, Bantayan, Nathan Ross B., Cruz, Linnaeus Louisse A., Arias-Aguirre, Eloise, Aguirre, Zedrick, Varona, Michelle Capahi, Co, Elaiza Marie Fernandez, Lumbang, Grace Nooriza Opay, Enkhmaa, Byambaa

“…The use of alirocumab and evolocumab is generally safe and well-tolerated. However, concerns remain about their long-term safety, especially with regard to…”
Get full text

Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials by Rivera, Frederick Berro, Bantayan, Nathan Ross B., Aparece, John Paul, Cruz, Linnaeus Louisse A., Magallong, John Vincent, Pine, Polyn Luz, Idian-Javier, Anne Mira Nicca, Lumbang, Grace Nooriza O., Lerma, Edgar V., Lara-Breitinger, Kyla M., Gulati, Martha, Vijayaraghavan, Krishnaswami

“…•Women with type 2 diabetes and ethnic minorities remain underrepresented across multiple GLP-1RA cardiovascular outcome trials.•GLP-1 receptor agonists…”
Get full text

Trends of nonalcoholic fatty liver research in Southeast Asia from 2004 to 2022: A bibliometric analysis by Josol, Vivien Joyce D., Salvador, Paul Benedic U., Cruz, Linnaeus Louisse A., Ornos, Eric David B., Tantengco, Ourlad Alzeus G.

Get full text

Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression by Rivera, Frederick Berro, Cha, Sung Whoy, Magalong, John Vincent, Bantayan, Nathan Ross B, Cruz, Linnaeus Louisse A, Arias-Aguirre, Eloise, Aguirre, Zedrick, Varona, Michelle Capahi, Co, Elaiza Marie Fernandez, Lumbang, Grace Nooriza Opay, Enkhmaa, Byambaa

“…The use of alirocumab and evolocumab is generally safe and well-tolerated. However, concerns remain about their long-term safety, especially with regard to…”
Get full text